contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


virogates-announces-a-reorganisation-of-its-marketing-and-sales-department-and-revises-its-guidance-for-the-year

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Virogates er aktiv inden for medicinsk teknologi. I dag udføres forretningsdrift inden for forskning og udvikling af biomarkører og diagnostiske instrumenter til sundhedsindustrien. Produkterne sælges under forskellige mærker og bruges til identifikation, analyse og videre behandling af sygdomme, hovedsageligt hjerte -kar -sygdomme, kræft og neurologiske sygdomme. Virksomheden blev etableret i 2001 og har sit hovedkontor med beliggenhed i Birkerød.

Virogates

Company Announcement no. 11/2024 (December 16, 2024)Inside InformationBIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for ...

<div class="mfn-header mfn-header-denmark">Company Announcement no. 11/2024 (December 16, 2024)</div><div class="mfn-body">Inside InformationBIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring the level of inflammation in individuals in health clinics and hospitals, announces that it will reorganise its business to strengthen its focus on the longevity and health segment and revises its financial guidance for 2024 accordingly.An increased focus on sales to the health and longevity segment, including customers such as private laboratories, health clinics, etc., entails a different and more substantial marketing presence, and resources will be added to this area accordingly. In addition, ViroGates must revalue its direct sales presence in selected markets that have historically focused on sales to the acute care segment.ViroGates has taken the first steps to implement the strategic change and is currently discussing it with the affected departments and individuals. As a result of the reorganisation, ViroGates expects some positions to be made redundant and will set aside severance costs in the 2024 financial statement.Consequently, ViroGates is revising its financial guidance for the year 2024. ViroGates now expects revenue between DKK 4.5 and 5 million and an EBIT of DKK -14.5 to -15.5 million.For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: <a rel="noopener" href="mailto:jk@virogates.com">jk@virogates.com</a>Certified Advisor: Västra Hamnen Corporate Finance Per Lönn Tel. (+46) 40 200 250, email: ca@vhcorp.seAbout ViroGates ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals in health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a rel="noopener" href="http://www.virogates.com/">www.virogates.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/bec0333f-2678-4b77-b689-690f0f1ffd60/20241216-virogates-comp-ann-11-vf.pdf" class="mfn-primary">20241216 ViroGates Comp Ann 11 VF</a></div>

ViroGates announces a reorganisation of its marketing and sales department and revises its guidance for the year